2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 337

Does a Best Practice Alert Improve RA Patient Referral to Preventative Cardiology?
Abstract Number: 2200

Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense?
Abstract Number: 544

Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?
Abstract Number: 826

Does Anti-Glomerular Basement (anti-GBM) Antibody Positivity Correlate with Relapse in Patients with Anti-GBM Disease?
Abstract Number: 296

Does Care By a Multidisciplinary Team Improve Outcomes in Rheumatoid Arthritis? a Randomized Controlled Study
Abstract Number: 771

Does Cognitive Function Change over-Time in Systemic Lupus Erythematosus?
Abstract Number: 2842

Does Leflunomide Have a Role in Giant Cell Arteritis?
Abstract Number: 437

Does Reduction in Mechanical Knee Joint Loading Explain the Beneficial Effects of Weight Loss in Overweight or Obese Patients with Knee Osteoarthritis?
Abstract Number: 1944

Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus Nephritis?
Abstract Number: 1326

Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with Familial Mediterranean Fever ?
Abstract Number: 2999

Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
Abstract Number: 2821

Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Abstract Number: 418

Dose-Response Relationship between Neuromuscular Electrical Stimulation and Muscle Function in Patients with Rheumatoid Arthritis
Abstract Number: 1899

Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
Abstract Number: 1112

Downregulated Expression of Interferon Regulatory Factor 8 in Circulating Monocytes Exhibits Pro-Fibrotic Phenotype in Patients with Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].